COVID-19 COVID-19
Conditions
Interventions
Group vaccine Coronavac by Sinovac,Group vaccine ASD1222 by Oxford - AstraZeneca,it depends on the vaccine that Thai MOPH supply to the hospital,it depends on the vaccine that Thai MOPH supply to the
1 Coronavac,2 ASD1222,3 pending,4 pending
Sponsors
Ratchadapiseksompotch Research Fund
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The subject is aged > 18 years 2. Subjects had no history of COVID-19 vaccination before enrollment 3. Subjects who can comply with trial procedures and are available for the duration of follow-up
Exclusion criteria
Exclusion criteria: 1. Subjects who received any other vaccines within 1 month prior to enrollment 2. Subjects who received blood or blood product or immunoglobulin within 3 months prior to enrollment 3. Subjects participating in any clinical trial with COVID-19 immunogenicity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion rate by neutralizing antibody 4 weeks, 6 and 12 months after complete immunization cPass SARS-CoV-2 Neutralization Antibody Detection Kit GenScript | — |
Secondary
| Measure | Time frame |
|---|---|
| Seroconversion rate by IgG 4 weeks, 6 and 12 months after complete immunization Enzyme-Linked Immunosorbent Assay (ELISA) ,Immunogenicity to variant strain 4 weeks after complete immunization Plaque reduction neutralization test PRNT,Immunogenicity by T cell 4 weeks after complete immunization IFN gamma ELISPOT | — |
Countries
Thailand
Contacts
Public ContactWatsamon Jantarabenjakul
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed